AWKN-P001 is a N-methyl-D-aspartate Receptor-Modulating Drug Used in Combination with Psycho-Social Support for the Treatment of Severe Alcohol Use DisorderToronto,…
Phase 2b study of RL-007 in CIAS patients continues to be on track to report data in 2H 2024 and…
Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS target…
Scottsdale, Arizona--(Newsfile Corp. - November 13, 2023) - Sibannac, Inc. (OTC Pink: SNNC), a Nevada corporation (the "Company"), announced the…
Toronto, Ontario--(Newsfile Corp. - November 10, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a…
GILBERT, AZ / ACCESSWIRE / November 9, 2023 / Gambit Recovery, a leading sober living company, is revolutionizing the approach…
Collaborating in Providing Mental Health Testing for Under-Resourced Middle and High School StudentsAURORA, IL / ACCESSWIRE / November 9, 2023…
Additional Exclusive License with NCSU Further Expands Reduced Nicotine Content Plant Breeding CapabilitiesBUFFALO, N.Y., Nov. 07, 2023 (GLOBE NEWSWIRE) --…
NEW YORK, NY / ACCESSWIRE / October 13, 2023 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing…
More than one-in-five patients seeking treatment for chronic pain are prescribed opioids at their initial visit, contributing to an opioid…